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de Sevilla, Seville and 6) CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem), Instituto de Salud Carlos III, Tarragona, SpainAbstractVery little information is available on the involvement of newly characterized adipokines in human immunodeﬁciency virus (HIV)/
antiretroviral therapy (ART)-associated lipodystrophy syndrome (HALS). Our aim was to determine whether apelin, apelin receptor,
omentin, RBP4, vaspin and visfatin genetic variants and plasma levels are associated with HALS. We performed a cross-sectional
multicentre study that involved 558 HIV type 1– infected patients treated with a stable highly active ART regimen, 240 of which had
overt HALS and 318 who did not have HALS. Epidemiologic and clinical variables were determined. Polymorphisms in the apelin, omentin,
RBP4, vaspin and visfatin genes were assessed by genotyping. Plasma apelin, apelin receptor, omentin, RBP4, vaspin and visfatin levels were
determined by enzyme-linked immunosorbent assay in 163 patients (81 with HALS and 82 without HALS) from whom stored plasma
samples were available. Student’s t test, one-way ANOVA, chi-square test, Pearson and Spearman correlations and linear regression
analysis were used for statistical analyses. There were no associations between the different polymorphisms assessed and the HALS
phenotype. Circulating RBP4 was signiﬁcantly higher (p < 0.001) and plasma omentin was signiﬁcantly lower (p 0.001) in patients with
HALS compared to those without HALS; differences in plasma levels of the remaining adipokines were nonsigniﬁcant between groups.
Circulating RBP4 concentration was predicted independently by the presence of HALS. Apelin and apelin receptor levels were
independently predicted by body mass index. Visfatin concentration was predicted independently by the presence of acquired
immunodeﬁciency syndrome. HALS is associated with higher RBP4 and lower omentin in plasma. These two adipokines, particularly
RBP4, may be a link between HIV/ART and fat redistribution syndromes.
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several adipokines having autocrine, paracrine and endocrine
effects. Since the discovery and characterization of leptin in
1994 [1], different adipokines have been involved in theClin Microbiol Infect 2015; 21: 711.e1–711.e8
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such as insulin resistance and dyslipidemia. In the human im-
munodeﬁciency virus (HIV) setting, in vitro and in vivo studies
have provided evidence for abnormal cytokine and adipokine
synthesis in individuals with HIV/antiretroviral therapy (ART)-
associated lipodystrophy syndrome (HALS), particularly of tu-
mor necrosis factor alpha, some interleukins, leptin and adi-
ponectin, among others [2–4]. Our group has studied the
relationship between HALS and its associated metabolic de-
rangements and several adipokines, among them resistin [5],
fatty acid binding protein [6], zinc-associated glycoprotein [7],
leptin and adiponectin [8]. Recent information indicates, how-
ever, that adipose tissue produces many more adipokines than
those mentioned above, such as apelin, omentin, retinol acid
binding protein 4 (RBP4), vaspin and visfatin [9]. Most of these
newly characterized adipokines have been linked to insulin
resistance in uninfected subjects, and information with respect
to their involvement in HALS is scarce [10].
To gain further insight into the role of these peptides with
hormone properties in HALS and its associated metabolic de-
rangements, we conducted the present study with a cohort of
Spanish white HIV-infected patients receiving ART with and
without HALS. Our objective was to assess the association of
apelin, apelin receptor, omentin, RBP4, vaspin and visfatin single
nucleotide polymorphisms and their circulating levels with
HALS and its metabolic complications. Additionally, given the
close relationship between adipose tissue and the immune
system [11,12], the link between these adipokines and several
immunovirologic variables was assessed.Patients and methodsDesign, setting and participants
This was a multicentre cross-sectional case–control study
which included 558 adult HIV type 1 (HIV-1)– infected patients
receiving ART, 318 without HALS and 240 with overt HALS.
The sample size was designed to ﬁnd differences of 13% in the
distribution of polymorphisms between groups; assuming a
proportion of 40% in the non-HALS risk category, a risk alpha
of 5% and a power of 80%, the number of individuals to be
included was 240 per group. These numbers have been useful
and reproducible for gene analyses of HIV-infected subjects
[13]. Patients were recruited consecutively between 2004 and
2006 at the HIV outpatient clinic of the participating hospitals.
Patients were selected from among those who were receiving
ART, deﬁned as the combination of two nucleoside reverse
transcriptase inhibitors plus either a nonnucleoside reverse
transcriptase inhibitor or protease inhibitor or inhibitors. All
the selected patients had to fulﬁl the following inclusion criteria:Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectage over 18 years, presence of HIV-1 infection, stable ART
regimen for at least 1 year and presence or absence of HALS
according to previously deﬁned standardized criteria. Exclusion
criteria were the presence of active opportunistic infections,
current inﬂammatory diseases or conditions, consumption of
drugs with known metabolic effects such as steroids (systemic,
inhaled or topical), antidiabetic or hypolipidaemic drugs and
hormones, and plasma C-reactive protein >1 mg/dL. Gene
studies of Apelin, omentin, RBP4, vaspin and visfatin were carried
out on all the 558 patients recruited, while circulating apelin,
apelin receptor, omentin, RBP4, vaspin and visfatin levels were
assessed in a subset of 163 patients (82 without HALS and 81
with HALS) from whom stored plasma samples, drawn when
enrolled, were available. Ethics committees from the partici-
pating institutions approved the project. Informed consent was
obtained from each participant.
Assessment of HALS
All patients were given a full physical examination to assess the
type (lipoatrophy, lipohypertrophy or mixed) and degree
(slight, moderate or severe) of lipodystrophy. Criteria for lip-
oatrophy were one or more of the following: loss of fat from
the face, arms and legs; prominent veins in the arms and legs;
and a thin bottom. Lipohypertrophy was deﬁned by the pres-
ence of one or more of the following criteria: increase in
abdominal perimeter, breast and/or neck fat deposition. We
deﬁned mixed lipodystrophy as at least one characteristic of
lipoatrophy and one of lipohypertrophy concomitantly present
in a given patient. Lipodystrophy was categorized in accordance
with a scale previously validated [14]: nil (0), slight (1), mod-
erate (2) and severe (3). Doubtful cases were excluded. This
categorization was evaluated in the face, arms, legs, buttocks,
abdomen, neck and breasts. The sum of the values corre-
sponding to each body area indicated the degree of lipodys-
trophy: nil (0), slight (1–6), moderate (7–12) and severe
(13–18) [5–8,14,15]. In this study we included only extreme
lipodystrophy phenotypes (nil vs. severe cases) in order to
avoid superposition between groups. To objectively assess the
distribution of visceral adipose tissue and subcutaneous adipose
tissue, a single-slice computed tomographic scan was per-
formed at the level of L4 in the 558 patients included in this
study. The surface of adipose tissue was measured in square
centimeters.
Laboratory methods
Collection of blood samples. Blood was drawn from a peripheral
vein after overnight fasting. Whole blood was used to deter-
mine CD4+ T cell count and for DNA isolation. Plasma and
serum were obtained by centrifugation and were stored
at −80°C until used.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 711.e1–711.e8
TABLE 1. Demographic and clinical characteristics of patients
categorized according to presence or absence of HALS
Characteristic
No HALS
(n [ 318)
HALS
(n [ 240) p
Age (years) 43.5 ± 9.5 45.5 ± 9.7 0.01
Male sex, n (%) 227 (71.4) 171 (71.3) 1
BMI (kg/m2) 22.9 ± 3.1 23.6 ± 2.8 0.01
Waist–hip circumference ratio 0.89 ± 0.09 0.93 ± 0.08 0.04
Subcutaneous abdominal fat tissue
(cm2)a
128.9 ± 61.3 50 ± 30.7 0.004
Visceral abdominal fat tissue (cm2)a 37.2 ± 27 110.2 ± 68 0.01
HCV infection, n (%) 120 (37.7) 79 (32.9) 0.23
HIV-1 risk group, n (%)
Homosexual 111 (34.9) 76 (31.7) 0.4
Heterosexual 93 (29.2) 81 (33.8) 0.35
Injection drug user 114 (35.8) 77 (32.1) 0.35
Other/unknown 0 6 (2.5) 0.004
Duration of HIV infection (years) 11.7 ± 5.7 13.7 ± 5.9 0.002
AIDS, n (%) 85 (26.7) 118 (49.1) <0.001
Current CD4+ T cell count (cells/mL) 474 ± 297 560 ± 308 0.04
Current log plasma HIV-1 load
(copies/mL)
2.6 ± 1.2 2.2 ± 0.8 <0.001
Current plasma HIV-1 load <200
copies/mL, n (%)
243 (76.4) 195 (81.3) 0.17
Exposure to NRTI before ART, yes,
n (%)
226 (71.1) 198 (82.5) 0.002
Duration of ART (months) 81 (37–117) 66 (44–126) 0.9
NRTI consumption, yes, n (%) 300 (94.3) 239 (99.6) <0.001
Cumulative time on NRTI (months) 128 (72–168) 159 (98–180) 0.05
NNRTI consumption, yes, n (%) 220 (69.2) 168 (70) 0.8
Cumulative time on NNRTI (months) 21 (11–36) 26 (15–54) 0.008
PI consumption, yes, n (%) 251 (78.9) 217 (90.4) <0.001
Cumulative time on PI (months) 47 (27–88) 55 (32–84) 0.15
AZT consumption, yes, n (%) 225 (70.8) 186 (77.5) 0.03
Cumulative time on AZT (months) 45 (24–80) 41 (10–61) 0.03
d4T consumption, yes, n (%) 156 (49.1) 196 (81.7) <0.001
Cumulative time on d4T (months) 37 (19–72) 39 (24–60) 0.93
Data are expressed as mean ± standard deviation or as median and IQR 25–75%.
Qualitative variables are expressed as percentages.
ART, antiretroviral therapy; AZT, zidovudine; BMI, body mass index; d4T,
stavudine; HALS, human immunodeﬁciency virus type 1/ART-related lipodystrophy
syndrome; HCV, hepatitis C virus; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aAssessed by computed tomographic scan at level of L4.
CMI Peraire et al. Novel adipokines and HALS 711.e3HIV-1 infection-related parameters. HIV-1 infection was diagnosed
by a positive enzyme-linked immunosorbent assay (ELISA) and
conﬁrmed by Western blot analysis. Plasma HIV-1 virus load
was determined by the Cobas Amplicor HIV-1 Monitor Test,
v1.5 (Roche Diagnostics, Barcelona, Spain). CD4+ T cell count
was analysed in a ﬂow cytometer FAC Scan (Becton Dickinson,
San Jose, CA, USA).
Blood chemistry. Concentrations of glucose, insulin, total
cholesterol, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol and triglycerides were measured using
standard enzymatic methods. The homeostasis model
assessment-estimated insulin resistance (HOMA-IR) method
(insulin (μIU/ml) × glucose (mmol/L)/22.5) was used to calcu-
late insulin resistance.
Assessment of polymorphisms. All the single nucleotide poly-
morphisms were validated by genotyping methods (KBio-
science, Herts, UK). The variations studied were the following:
Apelin, rs3761581 (G>T) and rs2235306 (C>T); Omentin,
rs2274910 (C>T); RBP4, rs3758538 (A>C), rs3758539 (A>G)
and rs34571439 (A>C); Vaspin, rs2236242 (A>T); and Visfatin,
rs1319501 (C>T), rs4730153 (A>G), rs10487818 (A>T) and
rs9770242 (A>C).
Apelin, apelin receptor, omentin, RBP4, vaspin and visfatin plasma
levels. Plasma omentin and visfatin concentration were deter-
mined in duplicate using commercial Omentin-1 human ELISA
and Visfatin (NAMPT) human ELISA kits, respectively (Bio-
Vendor, Heidelberg, Germany). Human RBP4 DuoSet and
Human Serpin A12 DuoSet kits (R&D Systems, Minneapolis,
MN, USA) were used to analyse plasma concentration of RBP4
and vaspin, respectively. Apelin and its receptor were deter-
mined using respective Human Apelin and Human Apelin re-
ceptor ELISA kits (Qayee-Bio, Shanghai, China). For each
adipokine, intra- and interassay variation coefﬁcients were,
respectively: apelin, 5.4% and 5.5%; apelin receptor, 5.8% and
6%; omentin, 4.1% and 4.8%; RBP4, 5.5% and 6.8%; vaspin, 5.5%
and 9.2%; and visfatin, 8.7% and 9.5%.
Statistical analyses
The statistical studies were carried out by SPSS software for
Windows, version 17.0 (IBM, Armonk, NY, USA). Firstly,
normal distribution and homogeneity of the variances were
assessed. Normally distributed data was expressed as
mean ± SD, whereas variables with a skew distribution were
represented as the median (25th percentile–75th percentile) or
transformed using the logarithm function. Categorical variables
were expressed as number (percentage). Qualitative variables
were analysed by the chi-square test or Fisher’s exact test when
necessary. Student’s t test and one-way ANOVA withClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InBonferroni post hoc test were used to compare continuous
variables between two groups and more than two groups,
respectively. To compare variables that did not ﬁt a Gaussian
distribution, we used the Mann-Whitney U and Kruskal-Wallis
tests in the same way. Associations between quantitative vari-
ables were evaluated by Pearson correlation analysis or
Spearman correlation for nonnormally distributed variables.
The independence of the observed associations was evaluated
by linear regression analysis. Differences with a p value of <0.05
were considered signiﬁcant for all statistical tests.ResultsCharacteristics of study population
Table 1 summarizes the demographic, clinical, immunovirologic
and treatment characteristics of the 558 patients, who were
separated by the presence or absence of HALS. All patients
from the HALS group had extreme lipodystrophy phenotype,
which included marked peripheral lipoatrophy severe enough
to be treated with facial implants. Concomitant centralfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 711.e1–711.e8
TABLE 3. Association between polymorphisms of apelin,
omentin, RBP4, vaspin and visfatin genes and presence of HALS
Gene Genotype No HALS (n [ 318) HALS (n [ 240) p
rs2235306
APELIN
C/T
T/T 306 (96.2) 228 (95) 0.34
T/C 9 (2.8) 6 (2.5)
C/C 3 (0.9) 6 (2.5)
Allele T 97.5% 96.5% 0.37
rs3761581
APELIN
G/T
T/T 303 (95.3) 233 (97.1) 0.21
T/G 8 (2.5) 6 (2.5)
G/G 7 (2.2) 1 (0.4)
Allele T 96.4% 98.3% 0.06
rs2274910
OMENTIN
C/T
C/C 155 (48.7) 114 (47.5) 0.39
T/C 124 (39) 104 (43.3)
T/T 39 (12.3) 22 (9.2)
Allele C 68.4% 69.4% 0.78
rs34571439
RBP4
A/C
A/A 198 (62.3) 152 (63.3) 0.46
C/A 110 (34.6) 76 (31.7)
C/C 10 (3.1) 12 (5)
Allele A 79.6% 79.4% 1
rs3758538
RBP4
A/C
A/A 233 (73.3) 174 (72.5) 0.89
C/A 73 (22.9) 55 (22.9)
C/C 12 (3.8) 11 (4.6)
Allele A 84.7% 83.8% 0.71
rs3758539
RBP4
A/G
G/G 207 (65.1) 162 (67.5) 0.06
A/G 105 (33) 66 (27.5)
A/A 6 (1.9) 12 (5)
Allele G 81.6% 81.3% 0.94
rs2236242
VASPIN
A/T
A/A 123 (38.7) 97 (40.4) 0.29
T/A 147 (46.2) 97 (40.4)
T/T 48 (15.1) 46 (19.1)
Allele A 61.8% 60.8% 0.79
rs1319501
VISFATIN
C/T
T/T 195 (61.3) 165 (68.8) 0.12
T/C 108 (34) 62 (25.8)
C/C 15 (4.7) 13 (5.4)
Allele T 78.5% 81.7% 0.21
rs4730153
VISFATIN
A/G
G/G 109 (34.3) 84 (35) 0.96
A/G 155 (48.7) 114 (47.5)
A/A 54 (17) 42 (17.5)
Allele G 58.7% 59% 0.97
rs9770242
VISFATIN
A/C
A/A 197 (61.9) 163 (67.9) 0.13
C/A 109 (34.3) 64 (26.7)
C/C 12 (3.8) 13 (5.4)
Allele A 79% 81.5% 0.33
rs10487818
VISFATIN
A/T
A/A 309 (97.2) 234 (97.5) 0.97
T/A 6 (1.9) 4 (1.7)
T/T 3 (0.9) 2 (0.8)
Allele A 98.3% 98.5% 0.81
HALS, human immunodeﬁciency virus type 1/antiretroviral therapy–related
lipodystrophy syndrome.
Genotypes are expressed as n (%); allele frequencies, %.
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Table 2 lists the metabolic parameters of the subset of 163
patients for whom plasma adipokine measurements were taken.
No differences were observed between this subset of patients
and the remaining 395 patients from whom plasma samples
were not available; the subset is thus representative of the
whole cohort.
Genetic association study
Table 3 lists genetic association study data. All genotypes and
allele frequencies studied were distributed according to the
predicted Hardy-Weinberg equilibrium, except for apelin
rs3761581G/T, apelin rs2235306C/T and visfatin rs10487818G/
T, which did not follow this distribution. None of the genetic
variants analysed was associated with HALS. Of note, plasma
omentin levels were associated with omentin rs2274910 poly-
morphism in patients with HALS, with carriers of the TT ge-
notype having lower plasma omentin levels than carriers of the
CC genotype (p 0.009). Otherwise, in patients without HALS,
plasma visfatin levels were signiﬁcantly lower in carriers of the
visfatin rs1319501 TT genotype than in carriers of the CC ge-
notype (p 0.004). No other polymorphisms in the adipokine
genes assessed appeared to inﬂuence plasma levels of the adi-
pokines for which they respectively encode.
Plasma levels of adipokines
HALS study. Fig. 1 shows the concentration of circulating apelin,
apelin receptor, omentin, RBP4, vaspin and visfatin in patients
categorized according to the presence or absence of lipodys-
trophy. Patients with HALS had signiﬁcantly lower plasma
omentin concentration (p 0.001) and signiﬁcantly higher plasma
RBP4 concentration (p < 0.001) compared to patients without
HALS. Patients with pure lipoatrophy had nonsigniﬁcantly
different circulating adipokine levels than patients with mixed
lipodystrophy.
Relationship between adipokines. We assessed the correlations
between plasma levels of the six adipokines determined. EachTABLE 2. Metabolic data of patients categorized according to
presence or absence of HALS
Characteristic
No HALS
(n [ 82)
HALS
(n [ 81) p
Glucose (mmol/L) 5.4 (4.8–6.2) 5.3 (4.7–6.3) 0.77
Insulin (μU/mL) 24.7 (17.9–31.4) 24.2 (14.8–37.8) 0.76
HOMA-IR 6.1 (4.4–9) 5.8 (3.6–9.9) 0.58
Cholesterol (mmol/L) 4.8 (4.1–6.2) 5.2 (4.3–6.4) 0.21
HDL cholesterol (mmol/L) 1 (0.9–1.3) 1 (0.9–1.3) 0.77
LDL cholesterol (mmol/L) 3.2 (2.5–4) 3.4 (2.5–4.2) 0.51
Triglycerides (mmol/L) 1.8 (1.2–2.4) 1.9 (1.2–3.5) 0.36
HALS, human immunodeﬁciency virus type 1/antiretroviral therapy–related
lipodystrophy syndrome; HDL, high-density lipoprotein; HOMA-IR, homeostasis
model assessment-estimated insulin resistance; LDL, low-density lipoprotein.
Data are expressed as median and IQR 25–75%.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcorrelation was assessed in the whole cohort and in the subsets
separately. In the whole cohort, omentin correlated with vaspin
(r = 0.26, p < 0.001) and with RBP4 (r = −0.16, p 0.04). RBP4
correlated with visfatin (r = −0.23, p < 0.001). In the HALS
subset, omentin correlated with visfatin, vaspin and apelin re-
ceptor (r = 0.31, r = 0.29 and r = 0.25 respectively, all p < 0.05);
visfatin correlated with vaspin (r = 0.44, p < 0.001), vaspin with
RBP4 (r = 0.470, p < 0.001) and RBP4 with apelin receptor
(r = −0.24, p 0.03). In patients without HALS, there was a
correlation between visfatin and RBP4 (r = −0.22, p 0.05).
Correlations with metabolic parameters. We assessed the corre-
lations between plasma levels of the six determined adipokines
and total cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, triglycerides, glycaemia, insulin
and HOMA-IR. Each correlation was assessed in the whole
cohort and in the subsets separately. For the entire cohort,
RBP4 correlated with triglycerides (r = 0.180, p 0.025), apelinious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 711.e1–711.e8
FIG. 1. Plasma apelin, apelin receptor, omentin, RBP4, vaspin and vis-
fatin in the subset of 163 patients categorized according to the absence
(n = 82) or presence (n = 81) of HALS. Plasma concentration of apelin,
apelin receptor, omentin, RBP4, vaspin, and visfatin are expressed as log
transformed and as mean ± standard deviation. HALS, human immu-
nodeﬁciency virus/antiretroviral therapy–related lipodystrophy
syndrome.
CMI Peraire et al. Novel adipokines and HALS 711.e5correlated with HOMA-IR (r = 0.215, p 0.007) and insulin
(r = 0.234, p 0.003) and apelin receptor correlated with glucose
(r = −0.214, p 0.008). In the HALS subset, the signiﬁcant cor-
relations observed were between RBP4 and triglycerides
(r = 0.246, p 0.032), and between apelin and insulin (r = 0.436,
p < 0.001) and HOMA-IR (r = 0.404, p < 0.001). In patients
without HALS, there were signiﬁcant correlations between
omentin and glucose (r = 0.238, p 0.033), between vaspin and
HOMA-IR (r = 0.222, p 0.048) and between apelin receptor
and glucose (r = −0.232, p 0.038).
Correlations with immunovirologic parameters. The correlations
between circulating adipokines and current plasma HIV virus
load and current CD4+ T cell count were evaluated, and each
correlation was assessed in the whole cohort and the subsets.
In the whole cohort, and as far as current HIV virus load is
concerned, omentin and visfatin had a positive correlation
(r = 0.193, p 0.02; and r = 0.181, p 0.032, respectively), while
RBP4 had a negative correlation (r = −0.220, p 0.008). In the
HALS subset, visfatin was signiﬁcantly correlated with current
HIV virus load (r = 0.379, p 0.001). In the non-HALS subset,
there was a correlation between apelin receptor and current
HIV virus load (r = −0.333, p 0.005) and between omentin and
current CD4+ T cell count (r = −0.277, p 0.023).
Regression analyses. The associations between circulating adi-
pokine levels and several demographic and clinical variables
(age, sex, body mass index (BMI), acquired immunodeﬁciencyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Insyndrome (AIDS), immunovirologic parameters, antiretroviral
drugs used, hepatitis C virus (HCV), metabolic parameters)
were assessed by Student’s t test and Spearman correlation.
The signiﬁcant associations observed in the univariate analysis
(data not shown) were further studied with linear regression
analyses considering the levels of apelin, apelin receptor
omentin, RBP4, vaspin and visfatin as dependent variables. Age,
BMI, the above-mentioned bivariate associations and those
observed in the univariate analysis of clinical parameters were
included as independent variables. For omentin, none of the
variables included in the multivariate analysis (age, BMI, HALS,
HCV, d4T consumption, current HIV virus load, CD4+ T cell
count) predicted circulating levels. Age, BMI, HCV, current HIV
virus load and AIDS were the variables included in the
regression model for visfatin (R = 0.598). AIDS was useful for
predicting visfatin concentration (B = 0.402; p 0.009). Regres-
sion model for vaspin was not constructed as a result of its lack
of associations with other variables. For RBP4, the model had a
multiple correlation coefﬁcient of R = 0.528, and circulating
RBP4 concentration was independently predicted by the pres-
ence of HALS (B = 0.261; p 0.024). Variables also included in
this model were the same as in omentin model plus tri-
glycerides, exposure to nucleoside reverse transcriptase in-
hibitors before ART and protease inhibitor consumption. As
circulating apelin levels are concerned, the model included age,
BMI, insulin, HOMA-IR and d4T consumption (R = 0.489), with
BMI being the only predictive factor (B = −0.011; p 0.039).
Plasma glucose levels, d4T consumption, age and BMI were
included in apelin receptor multivariate analysis (R = 0.513).
BMI was the only variable independently associated with plasma
apelin receptor levels (B = 0.011; p 0.03).DiscussionGiven that adipose tissue pathology and the prevalence of
metabolic derangements in obesity and HALS have some sim-
ilarities, investigators have suggested that these two conditions
share common pathophysiologic and molecular mechanisms
[16]. This has been demonstrated consistently with respect to
the involvement of some adipokines, such as leptin, adiponectin,
resistin and FABP4, among others [5–8]. In the present study,
we explored whether perturbations in apelin, apelin receptor,
omentin, RBP4, vaspin and visfatin (also known as nontradi-
tional adipokines, given that they have recently been charac-
terized, and their role in obesity and in insulin resistance is only
just starting to be explored) do exist in the HALS setting. Our
data indicate that genetic variants of these adipokines are not
associated with HALS; we found, however, that HALS patients
have changes in circulating omentin and RBP4, while thefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 711.e1–711.e8
711.e6 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIremaining adipokines assessed are not perturbed. A question
arises as to the reasons that might explain the positive associ-
ation of plasma adipokines with HALS while genetic variants
show no association. It could be speculated that the fat redis-
tribution itself, rather than the effect of genetic variants, is
responsible for the changes in circulating omentin and RBP4 in
the HALS setting, given the lack of association between HALS
and the polymorphisms assessed.
Omentin is secreted mainly in visceral adipose tissue and is
down-regulated in obesity and in diabetes [17]. Omentin is
regulated by insulin and glucose and has insulin-sensitizing
properties [18]. Recent data indicate that circulating omentin
levels are lower in nascent metabolic syndrome and that
omentin might have beneﬁcial effects in these patients [19].
There is so far no data regarding omentin in the setting of HIV-
infected patients. In this study, we observed that patients with
HALS had lower circulating levels of omentin compared to
those without HALS. This agrees with the ﬁnding that patients
with obesity [20] and with metabolic syndrome [19] have lower
levels of omentin. Surprisingly, however, omentin was not
correlated with any of the metabolic variables assessed. Addi-
tional interesting ﬁndings were the strong positive correlation
between omentin and HIV virus load, and the negative corre-
lation between omentin and CD4+ T cell count (in the non-
HALS subset only), suggesting an immunovirologic modula-
tory effect for this adipocytokine; omentin could therefore
represent a link between adipose tissue and immune system
[11,12] and merits further investigation.
RBP4 is the carrier of circulating retinol. It has been
convincingly demonstrated that it contributes to insulin resis-
tance in obesity and in type 2 diabetes mellitus [21,22]. In HIV-
infected patients, an Austrian study showed that ART increased
circulating RBP4 levels [23], the amount of which was subse-
quently reduced when rosiglitazone was added [24]. In-
vestigations carried out in South Korea and Taiwan indicate
strong association between RBP4 and metabolic syndrome or
insulin resistance [25,26], but as far as HALS is concerned,
studies in adults and in children have reported no such asso-
ciation [27,28]. Our data indicate that there is a correlation
between RBP4 and triglycerides. Retinol is a precursor in the
synthesis of the nuclear hormone receptors RXR and RAR [29].
RXR can form heterodimers with subfamily 1 nuclear receptors
like PPARs, which regulate the transcription of genes involved
in fatty acid metabolism [30]. This could explain the relationship
between RBP4 and triglycerides. Furthermore, we found that
HALS is associated with higher circulating RBP4 levels; in fact,
the presence of HALS was the strongest independent predictor
of RBP4 levels. The discrepancy between our results and those
reported previously might be due to those studies only having
small patient cohorts [27,28], which can yield unreliable data,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwhereas there are more than 80 patients per arm (with and
without HALS) in our cohort.
Apelin is an adipokine expressed in several cells, among them
the adipocytes. In uninfected subjects, apelin has been shown to
regulate insulin sensitivity [31] and seems to be a promising
therapeutic target for type 2 diabetes mellitus [32]. This is in
accordance with the strong correlation between apelin and
insulin resistance that we found in our patients, particularly in
those with HALS. Of note, it has been shown that apelin might
play a role in HIV infection, since the apelin receptor may act as
a HIV coreceptor in vitro [33] and apelin itself inhibits HIV entry
into the cell [34]. We have found that in humans infected with
HIV, the circulating apelin receptor associates negatively with
HIV virus load in patients without HALS, thus emphasizing a
potential involvement of this adipokine in some immunoviro-
logic events in patients infected with HIV.
Another recently characterized adipokine is vaspin, also
known as serpin. It is predominantly secreted in visceral adi-
pose tissue and exerts insulin-sensitizing actions [35]. Elevated
vaspin mRNA expression in adipose tissue and higher plasma
vaspin levels have been reported in patients with insulin resis-
tance, type 2 diabetes mellitus and obesity [36]. To our
knowledge, the present study is the ﬁrst to assess vaspin in HIV-
infected patients, and the data suggest that this adipokine is not
involved in HALS and in metabolic disturbances in the HIV
setting.
Visfatin is expressed and regulated mainly in adipose tissue. It
has strong insulin-mimetic activity and it has been implicated in
insulin resistance, metabolic syndrome, cardiovascular disease
and obesity [37,38]. Previous studies on HIV-infected patients
have shown that both ART [23] and rosiglitazone [24] increase
plasma visfatin levels; however, the relationship between vis-
fatin and metabolic derangements in infected patients is
inconsistent [23,39]. In our study, no association between
circulating visfatin and insulin resistance or dyslipidemia could
be established, thus conﬁrming the ﬁndings of Parﬁeniuk-
Kowerda et al. [39]. On the other hand, in the current study,
visfatin was positively associated with plasma virus load and
with AIDS. Given that in vitro studies have shown that visfatin is
involved in HIV-Tat transactivating activity [40], and that it is
also able to inhibit HIV at an early stage in its life cycle [41], our
clinical data reinforce the potential involvement of visfatin in
HIV immunopathogenesis.
We acknowledge that the present study has some limita-
tions, among them the cross-sectional nature of our design,
which provides associations but not causality. Also, the multiple
comparisons performed in this study mean that some of the
associations that we found should be considered with caution.
In summary, we found a strong relationship between HALS
and omentin and RBP4, and the presence of HALSious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 711.e1–711.e8
CMI Peraire et al. Novel adipokines and HALS 711.e7independently predicted circulating RBP4 levels. Omentin,
apelin receptor and visfatin may be involved in HIV immuno-
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